The combination of the cancer types, variable age at onset, and discrepancy in family history of malignancy, with 15 of 24 families meeting updated Chompret criteria for LFS, supports a decreased penetrance and an attenuated phenotype for this TP53 variant. This evidence concerns the gene TP53 and cancer.